Particle.news
Investment Strategies Drug Sales Investment Opportunities Revenue Decline Investment Shifts Drug Demand Drug Pricing Stock Performance Sales Performance COVID-19 Impact Investment Biopharmaceutical Growth Out-licensing Online Sales Growth Growth Projections Argentina Price Increases Investment Deals Obesity Market Investment in Biotech Competition Sales Projections Generics
The pact underscores Chinese biotech’s rapid rise in global licensing, with Hengrui leading Phase I trials for the COPD asset before GSK’s later-stage development.
